title: Use of cold atmospheric plasma in the treatment of cancer.
abstract: Cold atmospheric plasma (CAP) is an emerging modality for the treatment of solid tumors. In-vitro experiments have demonstrated that with increasing doses of plasma, tumor cells assays display decreased cell viability. CAP is theorized to induce tumor cells into apoptosis via multiple pathways including reactive oxygen and nitrogen species as well as cell cycle disruption. Studies have shown CAP treatment can decrease mouse model glioblastoma multiforme tumor volume by 56%, increase life span by 60%, and maintain up to 85% viability of normal cells. Emerging evidence suggests that CAP is a viable in-vivo treatment for a number of tumors, including glioblastoma, as it appears to selectively induce tumor cell death while noncancerous cells remain viable.
authors: Department of Neurological Surgery, The George Washington University Medical Center, Washington, District of Columbia 20037.
authors: Parker
authors: P
authors: Babington
authors: Columbian College of Arts and Sciences, George Washington University, Washington, District of Columbia 20052.
authors: Kenan
authors: K
authors: Rajjoub
authors: US Medical Innovations, Takoma Park, Maryland 20912.
authors: Jerome
authors: J
authors: Canady
authors: Department of Neurological Surgery, The George Washington University Medical Center, Washington, District of Columbia 20037.
authors: Alan
authors: A
authors: Siu
authors: Department of Mechanical Engineering, The George Washington University, Washington, District of Columbia 20052.
authors: Michael
authors: M
authors: Keidar
authors: Department of Neurological Surgery, The George Washington University Medical Center, Washington, District of Columbia 20037.
authors: Jonathan H
authors: JH
authors: Sherman
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism* / Q000494:pharmacology; D017209:Apoptosis; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D058626:Plasma Gases / Q000627:therapeutic use*; D026361:Reactive Nitrogen Species / Q000378:metabolism* / Q000494:pharmacology; D017382:Reactive Oxygen Species / Q000378:metabolism* / Q000494:pharmacology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D058626:Plasma Gases; D026361:Reactive Nitrogen Species; D017382:Reactive Oxygen Species